TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究*

doi:10.3969/j.issn.1672-5069.2023.01.030

Abstract

Abstract: Objective The aim of this study was to observe the clinical efficacy of camrelizumab therapy after transhepatic arterial chemoembolization (TACE) in the treatment of patients with advanced primary liver cancer (PLC). Methods A total of 116 patients with advanced PLC were admitted to Suzhou First People's Hospital between March 2018 and March 2021, and randomly divided into control and observation group, with 58 patients in each group. The patients in the control group were treated with TACE, and those in the observation group were treated with TACE and after that the carrierizumab was given for six months to one year. Serum alpha fetoprotein (AFP), alpha fetoprotein heterogeneity-L3 (AFP - L3) and carcinoembryonic antigen (CEA) levels were detected by ELISA. The peripheral blood T lymphocyte subsets were determined by FCM. The survival curve was drawn by Kaplan-Meier and compared by Log-Rank test. Results At the end of three month treatment, the complete remission, partial remission, stable disease, objective remission rate and disease control rate in the observation group were 8.6%, 48.3%, 29.3%, 56.9% and 86.2%, much superior to 1.7%, 36.2%, 31.0%, 37.9%(P<0.05) and 69.0%(P<0.05) in the control group; serum AFP, AFP - L3 and CEA were(86.5±28.7)ng/mL, (183.7±61.4)ng/mL and (9.1±2.6)ng/mL, significantly lower than [(185.8±34.9)ng/mL, 270.3±71.5)ng/mL and (25.4±3.6)ng/mL, respectively, P＜0.05] in the control; the percentage of peripheral blood CD4^＋ cells and the CD4^＋/CD8^＋ cell ratio were (38.6±4.1)% and (1.3±0.2), both significantly higher than [(32.3±3.7)% and (1.1±0.1), respectively, P＜0.05] in the control; up to the end of two-year follow-up, the survival rate in the observation group with two missed was 64.3%(36/56), much higher than 43.9%(25/57, x²=3.618, P=0.045) in the control with one missed. Conclusion We recommend the carlizumab therapy after TACE in the treatment of patients with advanced PLC, which needs further clinical investigation.

Key words: Hepatoma, Transhepatic arterial chemoembolization, Carrelizumab, Therapy, Prognosis

Du Shangyun, Weng Li, Wu Min. Clinical observation of camrelizumab therapy after TACE in the treatment of patients with advanced primary liver cancer[J]. Journal of Practical Hepatology, 2023, 26(1): 116-119.

References

[1] Luo Y, Jiang Y. Comparison of efficiency of TACE plus hifu and TACE alone on patients with primary liver cancer. J Coll Physicians Surg Pak, 2019, 29(5):414-417.
[2] 徐宏伟, 孙德生, 徐惠亮, 等. 碳酸氢钠肝动脉灌注联合TACE治疗中晚期原发性肝癌的疗效观察.介入放射学杂志, 2021, 30(9):932-936.
[3] Sun Y, Ji S, Ji H, et al. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined withradiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer. J BUON, 2019, 24(4):1402-1407.
[4] Kim D, Lee J H, Moon H, et al. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model. Theranostics, 2021, 11(1):79-92.
[5] 刘秀芳, 张伟伟. 多学科协作干预模式在TACE治疗原发性肝癌患者中的应用效果.介入放射学杂志, 2021, 30(10):1057-1060.
[6] Peng Z, Wei J, Wang F, et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res, 2021, 27(11):3069-3078.
[7] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 31(6):833-839.
[8] Han K, Kim J H. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol, 2015, 21(36):10327-10335.
[9] Marina O, Suh J H, Reddy C A, et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. J Neurosurg, 2011, 115(2):220-229.
[10] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2):2411-247.
[11] Boyd M R, Paull K D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Devel Res, 2010, 34(2):91-109.
[12] Jin J, Zhou T, Lou J,et al. Efficacy of licartin combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced primary liver cancer. J BUON, 2020, 25(6):2584-2591.
[13] Xie L, Qian Z, Xu J. Clinical intervention effect of TACE combined with3DCRT in patients with primary liver cancer. Am J Transl Res, 2021, 13(7):7960-7967.
[14] Taylor A C, Maddirela D, White S B. Role of radioembolization for biliary tract and primary liver cancer. Surg Oncol Clin N Am, 2019, 28(4):731-743.
[15] Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut, 2020, 69(8):1492-1501.
[16] 李梅, 宋娟荣, 翟鹏涛, 等. 载药微球在原发性肝癌TACE治疗中疗效及安全性分析.介入放射学杂志, 2021, 30(2):186-190.
[17] Song H, Liu X, Jiang L, et al. Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1. Recent Pat Anticancer Drug Discov, 2021,16(3):312-332.
[18] 顾杰, 许晨, 周卫忠, 等. TACE联合阿帕替尼对比单独TACE治疗中晚期原发性肝癌的倾向性匹配分析. 介入放射学杂志, 2021, 30(7):724-729.
[19] 杨秋雨, 魏宁, 徐浩, 等. TACE联合卡瑞利珠单抗治疗中晚期肝癌短期疗效及疗效相关性分析. 医学影像学杂志, 2021, 31(7):1212-1219.
[20] Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the escort-1st randomized clinical trial. JAMA, 2021, 326(10):916-925.
[21] Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med, 2021, 9(3):305-314.
[22] Reguart N, Reyes R. Spotlight on camrelizumab in advanced squamous lung cancer: another feather in the cap of Chinese checkpoint inhibitors. J Thorac Oncol, 2022, 17(4):477-480.

Clinical observation of camrelizumab therapy after TACE in the treatment of patients with advanced primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Shen Yan, Chen Lin. Endoscopic treatment and long-term management of patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 8-10.
[2]	Zhang Dan, Jiang Jianxin. Comparison of response to recombinant cytokine gene-derived protein or human interferon α-2b and entecavir combination in the treatment of patients with serum HBeAg positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(1): 27-30.
[3]	Shao Simeng, Gao Feng, Jiang Lei, et al. Polarization of peripheral blood macrophages and PBMCs TXNIP/NLRP3 mRNA changes in patients with hepatitis B virus acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2023, 26(1): 63-66.
[4]	Zhu Xinwen, Wang Weibing, Yuan Fubing, et al. Combination of NLR and serum IL-6 level in predicting 28-day mortality in patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2023, 26(1): 67-70.
[5]	Li Susu, Dong Yuan, Jia Haoyan, et al. Observation of ornithine aspartate at base of colon dialysis in treatment of patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2023, 26(1): 75-78.
[6]	Dai Huan, Li Kai, Zhu Yongxiang, et al. Efficacy of endoscopic ligation and tissue glue injection in the treatment of patients with hepatitis B liver cirrhosis and esophageal and gastric varices bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 87-90.
[7]	Jiang Huizhen, Chen Jun, Chen Chunmei, et al. Performance of quantitative parameters by dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of benign and malignant hepatic space-occupying lesions [J]. Journal of Practical Hepatology, 2023, 26(1): 100-103.
[8]	Gao Xiangrui, Liu Hongyan, Zhang Huai, et al. Differential diagnosis of hepatic hemangioma and hepatocellular carcinoma by multi-b-value diffusion-weighted imaging of high-field magnetic resonance [J]. Journal of Practical Hepatology, 2023, 26(1): 104-107.
[9]	Ding Haibin, Zhang Xin, Li Ya, et al. TACE with sequential microwave ablation followed by oral sorafenib maintenance in treatment of patients with large hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2023, 26(1): 108-111.
[10]	Peng Yu, Li Haitao, Yang Wenli, et al. Clinical efficacy of PD-1 inhibitor and lenvatinib in the treatment of elderly patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(1): 112-115.
[11]	Dong Xianjin, Su Wei, Li Liansheng, et al. Comparison of laparoscopic hepatectomy and open hepatectomy in the treatment of patients with intrahepatic cholangiocarcinoma [J]. Journal of Practical Hepatology, 2023, 26(1): 120-123.
[12]	Yin Qiushi, Wang Xueguo, Song Qifeng. Clinical efficacy of laparoscopic hepatectomy in the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(1): 124-127.
[13]	Zhang Fu, Chen Junmao, Liang Xiaohui. Efficacy of primary suture laparoscopic common bile duct exploration in the treatment of patients with choledocholithiasis [J]. Journal of Practical Hepatology, 2023, 26(1): 128-131.
[14]	Liu Songhang, Gao Youkui, Cao Liangqi. Clinical efficacy of LC and ERCP in the treatment of patients with gallbladder and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(1): 132-135.
[15]	Zhang Wei, Hou Wei, Liu Hui, et al. Recurrence three years after liver transplantation of patients with idiopathic portal hypertension: A case report and literature review [J]. Journal of Practical Hepatology, 2023, 26(1): 136-139.